Molecular Analysis for Precision Oncology Virtual Congress

9-10 OCTOBER 2020

Chairs:
Fabrice André, Villejuif, France (Unicancer)
John Haanen, Amsterdam, Netherlands (ESMO)
Charles Swanton, London, UK (CRUK)

Organising partners:

map-onco.net
Welcome

MAP is a leading congress in precision medicine in oncology, established by key opinion leaders in the field. The name of the Congress was recently changed into Molecular Analysis for Precision Oncology to better reflect its aims of focusing on science, translational research, education and collaboration.

The MAP 2020 Virtual Congress will offer the same top-tier scientific research and education and industry engagement that congress attendees are accustomed to, in an all-new digital environment.

By attending MAP 2020, participants will learn how to integrate insights from tumour sample analysis into daily practice, how to seek and identify actionable mutations in patient DNA and how to provide the best possible personalised treatment.

Founded by Jean-Charles Soria, Fabrice André and Charles Swanton, the MAP Congress has established itself as a point of reference for all specialists wishing to create a bright future for precision medicine in oncology, by delivering a highly specific, minimally toxic and dramatically effective treatment for each patient.

The MAP Congress is the result of a close partnership among Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and Unicancer, all committed to offering the best care to people with cancer worldwide, through oncology education and research.

We look forward to welcoming you online at the MAP 2020 Virtual Congress.

In the meantime, we hope you and your families stay safe and well.

Yours sincerely,

MAP 2020 Scientific Co-Chairs

Fabrice André, Villejuif, France
Unicancer

John Haanen, Amsterdam, Netherlands
ESMO

Charles Swanton, London, UK
CRUK
Congress Officers

SCIENTIFIC COMMITTEE CO-CHAIRS
Fabrice André, Villejuif, France (Unicancer)
John Haanen, Amsterdam, Netherlands (ESMO)
Charles Swanton, London, UK (CRUK)

SCIENTIFIC COMMITTEE
Geneviève Almouzni, Paris, France
Alberto Bardelli, Candiolo, Italy
Jean-Yves Blay, Lyon, France
Mariam Jamal-Hanjani, London, UK
Leeat Keren, Stanford, CA, USA
Sherene Loi, Melbourne, Australia
Sergio Quezada, London, UK
Wouter Scheper, Amsterdam, Netherlands
James Thaventhiran, Cambridge, UK
Daniela Thommen, Amsterdam, Netherlands
Clare Turnbull, London, UK

LEARNING OBJECTIVES
✓ Update your knowledge on molecular targets for the most frequent cancers
✓ Acquire a better understanding on tumour biology-related mechanisms as potential targets and resistance to therapy
✓ Follow-up on new data in Immuno-oncology (Mechanisms of toxicity, prognostic/predictive markers for therapy and monitoring)
✓ Learn about new targets and effectors (Gene Editing, CarT cells, Antibody-drug conjugates)
Programme

For the full and most updated overview, please visit the online programme.

FRIDAY, 9 OCTOBER 2020

12:00-12:10  Opening and Welcome
Welcome to MAP 2020, Scientific Committee Co-Chairs

12:10-13:20  Session 1: Molecular targeting
Chair: F. André, Villejuif, France
Metastatic lung cancer, F. Barlesi, Villejuif, France
Colon, M. Chalabi, Amsterdam, Netherlands
Bladder cancer, F. Radvanyi, Paris, France
Prostate, J. S. de Bono, London, UK
Live discussion

13:35-14:30  Session 2: Epigenetics
Chair: G. Almouzni, Paris, France
Chromatin remodelling, J. Downs, London, UK
Epigenetics and antitumor immunity, G. Almouzni, Paris, France
Epigenetics and intratumor heterogeneity, R. Margueron, Paris, France
Live discussion

14:45-15:40  Session 3: Mechanisms of IO toxicity
Chairs: J. Thaventhiran, Cambridge, UK; J. Haanen, Amsterdam, Netherlands
Genes regulating human immunity and care for patients with gene deficiencies in pathways targeted by checkpoint blockade, J. Thaventhiran, Cambridge, UK
Serum autoantibodies and irAEs, J. Hassel, Heidelberg, Germany
Interplay between steroids, immune targeting and GI toxicity, T. Kirchhoff, New York, NY, USA
Live discussion
**FRIDAY, 9 OCTOBER 2020**

**15:55-17:05 Session 4: Clonal evolution**

**Chairs:** M. Jamal-Hanjani, London, UK; A. Bardelli, Candiolo, Italy

Therapy-induced mutagenesis and drug resistance in colon cancer, A. Bardelli, Candiolo, Italy

Tumour evolution from early to late stage disease in lung cancer, M. Jamal-Hanjani, London, UK

The co-evolution of the genome and epigenome in colorectal cancer, A. Sottoriva, Sutton, UK

Quantifying tumour evolution through treatment and metastasis, C. Curtis, Stanford, CA, USA

Live discussion

---

**17:20-18:00 Mini Oral session**

**Chair:** F. André, Villejuif, France

1MO - A proteomics-based platform for predicting response to immunotherapy and personalizing treatment plans, Y. Shaked, Haifa, Israel

Live Q&A

2MO - Radiotherapy in cancer is associated with a deletion signature that contributes to poor patient outcomes, E. Kocakavuk, Farmington, CT, USA

Live Q&A


Discussion, K. Litchfield, London, UK

4MO - MET exon 14 screening strategy, how not to miss large deletions, R. Loyaux, Paris, France

Discussion, A. Stenzinger, Heidelberg, Germany
**SATURDAY, 10 OCTOBER 2020**

**12:00-12:25**  
**Keynote address: Gordon Peters Lecture**  
*Chair: C. Swanton, London, UK*  
KRAS, M. Barbacid Montalbán, Madrid, Spain

**12:40-13:50**  
**Session 5: Biomarkers for immunotherapeutics**  
*Chair: S. Loi, Melbourne, Australia*  
- B cells and tertiary lymphoid structures as biomarkers for immunotherapy, *W. Fridman, Paris, France*  
- Predictive value of the microbiome for immunotherapy, *L. Zitvogel, Villejuif, France*  
- Multimodal genomic features to predict outcome of immune checkpoint blockade, *E. Anagnostou, Baltimore, MD, USA*  
- Immune biomarkers and novel immunotherapeutics, *S. Loi, Melbourne, Australia*  
Live discussion

**14:05-15:00**  
**Session 6: New technologies for therapeutic targeting**  
*Chair: J. Haanen, Amsterdam, Netherlands*  
- Gene editing: CRISPR editing of T cells for TCR gene therapy, *D. Busch, Munich, Germany*  
- Antibody drug conjugates: For more mechanistic data on ADC compounds and combination therapy, *D. Peeper, Amsterdam, Netherlands*  
Live discussion
15:15-16:25 Session 7: Pancreatic cancers
Chair: A. Maitra, Houston, TX, USA
Identifying high risk populations in pancreatic cancer using computational approaches, N. Malats, Madrid, Spain
Stromal heterogeneity in pancreatic cancer, G. Biffi, Cambridge, UK
Regulation of tumour biology by stromal components, C. Jorgensen, Manchester, UK
Clinical implications of last advances in pancreatic cancers, A. Maitra, Houston, TX, USA
Live discussion

16:40-17:35 Session 8: In-situ tissue interpretation
Chair: L. Keren, Stanford, CA, USA
Germline genetics, C. Turnbull, London, UK
Unravelling the tumour microenvironment by multiplexed imaging, L. Keren, Stanford, CA, USA
Imaging immune cell dynamics and function, C. Zhao, Bethesda, MD, USA
Live discussion